Hep C Discussion Forum

Summary from CROI 2014 for Hepatitis HCV direct acting antivirals (DAAs) in HCV and HIV/HCV coinfection: same outcome? Which DAA regime will allow for the shortest treatment duration?

From the 21st Conference on Retroviruses and Opportunistic Infections, Boston, MA March 3 - 6, 2014

An interesting and informative article on clinical trial results for HCV/HIV co-infected persons, including data from triple HCV therapy with PEG-IFN/RBV and first or second wave HCV protease inhibitor such as telaprevir, boceprevir or faldaprevir or simeprevir, as well as the results from the first IFN-free study (PHOTON-1) of sofosbuvir and ribavirin.

Overall, these results demonstrate that interferon-free treatment strategies are a very close reality for the majority of patients. As response rates are virtually superimposable to findings in monoinfected patients these findings also underline that probably HIV patients no longer should be treated as an independent patient population (other than for their potential for drug-drug interactions between HCV drugs and antiretroviral therapy) but on average can be treated like HCV mono-infected subjects.

See full article...

http://www.natap.org/2014/CROI/croi_110.htm